The Tobacco Control Program (Program) is the focal point for University of California, San Francisco (UCSF) scientists in disciplines ranging from the molecular biology of nicotine addiction through political science. These scientists combine their efforts to eradicate the use of tobacco and tobacco-induced cancer and other diseases worldwide. A strong theme is that science-driven policy and public health interventions are key to ending the tobacco epidemic, as well as biological and clinical science. The role of the tobacco industry has been an important focus. The specific scientific goals are to conduct clinical and laboratory investigations of the mechanisms of nicotine addiction;to further understand the effects of tobacco use and exposure to second-hand tobacco smoke, including genetic studies and investigations of racial and ethnic differences in measures of tobacco exposure and tobacco-related diseases;to develop and test innovative interventions for tobacco users, especially those in high-risk populations, including youth, individuals co-morbid with mental and substance abuse disorders, chronic smokers, and ethnic minorities;to provide estimates of the economic costs of tobacco use to society and the corresponding benefits of tobacco control programs;to conduct research on tobacco related policy and to continue to study the effects of the tobacco industry, both nationally and internationally, on tobacco use;and to better describe populations with high smoking rates, both in this country and internationally. Rather than being distinct areas of work, these investigations often interact with, and benefit from each other, spanning multiple disciplines. The expertise inherent of the Program membership supports the accomplishment of these goals. Tobacco Control Program work is grouped into five themes: (1) studies of nicotine and tobacco effects, metabolism and biomarkers, including second hand smoke;(2) clinical interventions;(3) the economics of tobacco control;(4) the tobacco industry;and (5) descriptive and epidemiological studies. Since the last competitive review of the Helen Diller Family Comprehensive Cancer Center (Center), the productivity of the Program has increased, new faculty have been mentored and added to the roster, and collaboration across disciplines is increasingly evident. The Program has 20% intra-programmatic and 10% inter-programmatic publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-15
Application #
8567890
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
15
Fiscal Year
2013
Total Cost
$96,485
Indirect Cost
$90,775
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Ryu, Jae Kyu; Rafalski, Victoria A; Meyer-Franke, Anke et al. (2018) Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol 19:1212-1223
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28
Tat, David; Kenfield, Stacey A; Cowan, Janet E et al. (2018) Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSUREā„¢). Prostate 78:32-39
Guydish, Joseph; Tajima, Barbara; Le, Thao et al. (2018) Do cigarette graphic warnings encourage smokers to attend a smoking cessation programme: a quasi-experimental study. Tob Control 27:43-49

Showing the most recent 10 out of 192 publications